Urogen Pharma LTD 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
UroGen Pharma Ltd. announced substantial revenue increases driven by Zusduri sales, alongside continued investment in its product pipeline and operational expansion.
NASDAQ
Urogen Pharma Ltd. announced a Second Amended and Restated Loan Agreement, increasing its credit facility to $250 million with BioPharma Credit PLC.
NASDAQ
UroGen Pharma reports Q3 2025 results, highlighting the commercial launch of Zusduri, progress in its RTGel pipeline, and a significant lease extension for its Princeton headquarters, alongside increased operating losses.
NASDAQ
UroGen Pharma reported increased revenue from Jelmyto sales but wider net losses in Q2 2025, alongside the significant FDA approval of Zusduri and progress in its pipeline.
NASDAQ
10-Q: UroGen Pharma Reports First Quarter 2025 Financial Results; UGN-102 PDUFA Date Remains on Track
UroGen Pharma announces its financial results for the first quarter of 2025, highlighting revenue growth and continued progress towards the PDUFA date for UGN-102.
NASDAQ
UroGen Pharma's Q3 2024 results show increased revenue and progress in clinical trials, particularly for UGN-102, while also highlighting ongoing losses and strategic financial activities.
NASDAQ
UroGen Pharma's second quarter 2024 results show increased revenue and ongoing clinical development of key product candidates.
NASDAQ
UroGen Pharma's first quarter 2024 results show increased revenue from Jelmyto sales and ongoing progress in clinical development programs.